5-(N-Boc-N-methylamino)-1,2-epoxypentane | 497107-76-3

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: 5-(N-Boc-N-methylamino)-1,2-epoxypentane
• 英文别名: tert-Butyl methyl(3-(oxiran-2-yl)propyl)carbamate；tert-butyl N-methyl-N-[3-(oxiran-2-yl)propyl]carbamate
• CAS: 497107-76-3
• 化学式: C₁₁H₂₁NO₃
• 分子量: 215.293
• InChiKey: DNACUGFUHHLHTJ-UHFFFAOYSA-N

物化性质

• 沸点：
  279.2±9.0 °C(Predicted)
• 密度：
  1.034±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.5
• 重原子数：
  15
• 可旋转键数：
  6
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.91
• 拓扑面积：
  42.1
• 氢给体数：
  0
• 氢受体数：
  3

安全信息

• 危险性防范说明：
  P261,P264,P270,P271,P280,P301+P312,P302+P352,P304+P340,P305+P351+P338,P330,P332+P313,P337+P313,P362,P403+P233,P405,P501
• 危险性描述：
  H302,H312,H315,H319,H332,H335

反应信息

• 作为反应物：
  描述：

  2,2,6,6-四甲基哌啶 、 5-(N-Boc-N-methylamino)-1,2-epoxypentane 在 正丁基锂 作用下， 以 四氢呋喃 、 正己烷 为溶剂， 反应 1.25h， 以63%的产率得到1-(5-N-Boc-N-methylaminopent-1-enyl)-2,2,6,6-tetramethylpiperidine
  参考文献：
  名称：

  来自末端环氧化物和受阻锂酰胺的烯胺

  摘要：

  氨基锂与环氧化物的新反应模式导致受阻烯胺。描述了这些烯胺中的一些与未活化的伯和仲烷基卤化物的反应，这扩大了可用于合成单烷基化醛的亲电子试剂的范围。

  DOI：

  10.1021/ja031770o
• 作为产物：
  描述：

  2-甲基-2-丙基4-戊烯-1-基氨基甲酸酯 在 sodium hydride 、 间氯过氧苯甲酸 作用下， 以 四氢呋喃 、 二氯甲烷 、 N,N-二甲基甲酰胺 为溶剂， 反应 24.0h， 生成 5-(N-Boc-N-methylamino)-1,2-epoxypentane
  参考文献：
  名称：

  Straightforward synthesis of α,β-epoxysilanes from terminal epoxides by lithium 2,2,6,6-tetramethylpiperidide-mediated deprotonation-in situ silylation

  摘要：

  Lithiation-in situ silylation of simple terminal epoxides using lithium 2,2,6,6-tetramethylpiperidide in combination with trimethylsilyl chloride provides a direct and experimentally convenient process for the synthesis of trans-alpha,beta-epoxysilanes. (C) 2002 Elsevier Science Ltd. All rights reserved.

  DOI：

  10.1016/s0040-4039(02)01893-2

文献信息

• Synthesis and <i>C</i>-Alkylation of Hindered Aldehyde Enamines
  作者：David M. Hodgson、Christopher D. Bray、Nicholas D. Kindon、Nigel J. Reynolds、Steven J. Coote、Joann M. Um、K. N. Houk

  DOI：10.1021/jo802016t

  日期：2009.2.6

  hindered lithium amides with terminal epoxides is described whereby aldehyde enamines are produced via a previously unrecognized reaction pathway. Some of these aldehyde enamines display unprecedented C-alkylation reactivity toward unactivated primary and secondary alkyl halides. For comparison, the reactivity of aldehyde enamines synthesized via a traditional condensation method was examined. C- rather

  描述了一种新的受阻锂酰胺与末端环氧化物的反应模式，其中醛烯胺是通过以前无法识别的反应途径生成的。这些醛烯胺中的一些对未活化的伯和仲烷基卤显示出前所未有的C-烷基化反应性。为了比较，检查了通过传统缩合方法合成的醛烯胺的反应性。在一系列亲电试剂中，C-而不是N-烷基化是主要的反应途径，这使得从α-烷基化的醛到合成烷基的途径比以前报道的更有用。
• Sultones and Sultines via a Julia-Kocienski Reaction of Epoxides
  作者：Geoffrey M. T. Smith、Paul M. Burton、Christopher D. Bray

  DOI：10.1002/anie.201508467

  日期：2015.12.7

  The development of the homologous Julia–Kocienski reaction has led to the discovery of two new reaction modes of epoxides with sulfones. These pathways allow rapid and direct access to a range of γ‐sultones and γ‐sultines.

  同源的Julia–Kocienski反应的发展导致发现了两种环氧化物与砜的新反应模式。这些途径可以快速，直接地获得一系列的γ-磺内酯和γ-磺胺类药物。
• NOVEL AZALIDE AND AZALACTAM DERIVATIVES AND PROCESS FOR THE PRODUCTION OF THE SAME
  申请人：Meiji Seika Kaisha, Ltd.

  公开号：EP1661904A1

  公开（公告）日：2006-05-31

  A compound represented by the following general formula (1) or a pharmaceutically acceptable salt thereof, which is useful for a prophylactic and/or therapeutic treatment of a microbial infectious disease. [R1 is hydrogen atom, or a linear C1-6 alkylcarbonyl group; R2 is hydrogen atom, or a C1-6 alkylcarbonyl group; R3 is hydrogen atom, a C1-6 alkyl group, a C1-6 alkylcarbonyl group, a C1-6 alkenyl group, a C2-6 alkenylcarbonyl group, a C2-6 alkynyl group, or an Ar-B- group (Ar represents an aryl group, or a heterocyclic group, and B is a C1-6 alkyl group, a C1-6 alkylcarbonyl group, a C2-6 alkenyl group, a C2-6 alkenylcarbonyl group, or a C2-6 alkynyl group); R5, R6, R7, and R8 represent hydrogen atom, a C1-6 alkyl group, a C2-6 alkenyl group, a C2-6 alkynyl group, or an Ar-B'- group (B' is a C1-6 alkyl group, a C2-6 alkenyl group, or a C2-6 alkynyl group); X is oxygen atom, or an -NR4- group (R4 is hydrogen atom, a C1-6 alkyl group, or a C1-6 alkyl group which may be substituted with an Ar group); and R4' is hydrogen atom, or a group represented by the aforementioned formula (a) (R3" and R4" represent hydrogen atom, or a linear or branched C1-6 alkylcarbonyl group)]

  由以下一般式（1）表示的化合物或其药学上可接受的盐，可用于预防和/或治疗微生物感染性疾病。[R1为氢原子，或线性C1-6烷基羰基基团；R2为氢原子，或C1-6烷基羰基基团；R3为氢原子，C1-6烷基基团，C1-6烷基羰基基团，C1-6烯基基团，C2-6烯基羰基基团，C2-6炔基基团，或Ar-B-基团（Ar表示芳基团，或杂环基团，B为C1-6烷基基团，C1-6烷基羰基基团，C2-6烯基基团，C2-6烯基羰基基团，或C2-6炔基基团）；R5、R6、R7和R8表示氢原子，C1-6烷基基团，C2-6烯基基团，C2-6炔基基团，或Ar-B'-基团（B'为C1-6烷基基团，C2-6烯基基团，或C2-6炔基基团）；X为氧原子，或一个-NR4-基团（R4为氢原子，C1-6烷基基团，或C1-6烷基基团，可能被芳基取代）；R4'为氢原子，或由上述式（a）表示的基团（R3"和R4"表示氢原子，或线性或支链状C1-6烷基羰基基团）]
• Nozel azalide and azalactam derivatives and method for producing the same
  申请人：Miura Tomoaki

  公开号：US20070042974A1

  公开（公告）日：2007-02-22

  A compound represented by the following general formula (1) or a pharmaceutically acceptable salt thereof, which is useful for a prophylactic and/or therapeutic treatment of a microbial infectious disease. [R 1 is hydrogen atom, or a linear C1-6 alkylcarbonyl group; R 2 is hydrogen atom, or a C1-6 alkylcarbonyl group; R 3 is hydrogen atom, a C1-6 alkyl group, a C1-6 alkylcarbonyl group, a C1-6 alkenyl group, a C2-6 alkenylcarbonyl group, a C2-6 alkynyl group, or an Ar—B— group (Ar represents an aryl group, or a heterocyclic group, and B is a C1-6 alkyl group, a C1-6 alkylcarbonyl group, a C2-6 alkenyl group, a C2-6 alkenylcarbonyl group, or a C2-6 alkynyl group); R 5 , R 6 , R 7 , and R 8 represent hydrogen atom, a C1-6 alkyl group, a C2-6 alkenyl group, a C2-6 alkynyl group, or an Ar—B′— group (B′ is a C1-6 alkyl group, a C2-6 alkenyl group, or a C2-6 alkynyl group); X is oxygen atom, or an —NR 4 — group (R 4 is hydrogen atom, a C1-6 alkyl group, or a C1-6 alkyl group which may be substituted with an Ar group); and R 4′ is hydrogen atom, or a group represented by the aforementioned formula (a) (R 3″ and R 4″ represent hydrogen atom, or a linear or branched C1-6 alkylcarbonyl group)]

  下列通式（1）所代表的化合物或其药学上可接受的盐，可用于预防和/或治疗微生物感染性疾病。[其中R1为氢原子或线性C1-6烷基羰基基团；R2为氢原子或C1-6烷基羰基基团；R3为氢原子、C1-6烷基、C1-6烷基羰基基团、C1-6烯基、C2-6烯基羰基基团、C2-6炔基或Ar-B-基团（Ar代表芳基或杂环基，B为C1-6烷基、C1-6烷基羰基基团、C2-6烯基、C2-6烯基羰基基团或C2-6炔基）；R5、R6、R7和R8代表氢原子、C1-6烷基、C2-6烯基、C2-6炔基或Ar-B′-基团（B′为C1-6烷基、C2-6烯基或C2-6炔基）；X为氧原子或-NR4-基团（R4为氢原子、C1-6烷基或可被芳基取代的C1-6烷基）；R4′为氢原子或上述通式（a）所代表的基团（R3″和R4″代表氢原子或线性或支链状C1-6烷基羰基基团）]
• AZEPANYL-DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS COMPRISING THE SAME WITH ANTIPARASITIC ACTIVITY
  申请人：Merck Patent GmbH

  公开号：US20170137428A1

  公开（公告）日：2017-05-18

  The present invention provides compounds of Formula (i). Furthermore, pharmaceutical compositions are provided comprising at least one compound of Formula (i), for the treatment of parasitic diseases including malaria, as well as neurodegenerative diseases.